Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 184,201 | 94,819 | 224,947 | 71,660 | 171,332 |
| Marketable Securities | 233,627 | 196,557 | 2,495 | 145,366 | 483 |
| Receivables | 87,109 | 48,059 | 17,714 | 3,582 | 92 |
| Inventories | 4,372 | 2,620 | 3,107 | N/A | N/A |
| TOTAL | $522,782 | $356,705 | $256,131 | $225,375 | $175,952 |
| Non-Current Assets | |||||
| PPE Net | 11,665 | 2,314 | 1,468 | 957 | 755 |
| Investments And Advances | 3,870 | 3,000 | 631 | 371 | 0 |
| Intangibles | 7,366 | 8,326 | 3,867 | 0 | 0 |
| Other Non-Current Assets | 16,475 | 6,646 | 3,394 | 1,160 | 2,200 |
| TOTAL | $39,376 | $20,286 | $9,360 | $2,488 | $2,955 |
| Total Assets | $562,158 | $376,991 | $265,491 | $227,863 | $178,907 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 16,387 | 9,419 | 23,691 | 9,910 | 8,680 |
| TOTAL | $135,695 | $80,612 | $36,936 | $15,429 | $11,478 |
| Non-Current Liabilities | |||||
| Long Term Debt | 72,438 | 71,845 | 29,819 | 19,434 | N/A |
| Other Non-Current Liabilities | 10,599 | 0 | 1,748 | 100 | 699 |
| TOTAL | $83,037 | $71,845 | $31,567 | $19,534 | $699 |
| Total Liabilities | $218,732 | $152,457 | $68,503 | $34,963 | $12,177 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 42,557 | 38,377 | 34,219 | 26,732 | 20,709 |
| Common Shares | 6 | 6 | 5 | 5 | 4 |
| Retained earnings | -426,628 | -360,210 | -244,656 | -108,763 | -46,672 |
| Other shareholders' equity | 381 | 179 | -2 | -74 | 0 |
| TOTAL | $343,426 | $224,534 | $196,988 | $192,900 | $166,730 |
| Total Liabilities And Equity | $562,158 | $376,991 | $265,491 | $227,863 | $178,907 |